ImmunityBio Wins Saudi Approvals for ANKTIVA Cancer Therapies

ImmunityBio ( (IBRX) ) has shared an update.

On January 14, 2026, ImmunityBio announced that the Saudi Food and Drug Authority granted accelerated approval of ANKTIVA® (nogapendekin alfa inbakicept) in combination with immune checkpoint inhibitors for adult patients with metastatic non-small cell lung cancer whose disease has progressed following standard-of-care therapy, marking the first global approval for a subcutaneously administered IL-15 receptor superagonist and the first approval of this chemotherapy-free, NK- and T-cell–activating immunotherapy for this indication. On the same date, the SFDA also granted accelerated approval for ANKTIVA® plus Bacillus Calmette-Guérin (BCG) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease, underscoring ImmunityBio’s push into Middle East and North Africa oncology markets, supported by plans for a regional office in Saudi Arabia and a commercial partnership with BioPharma Cigalah; these approvals, based on clinical data from the QUILT trial program and backed by patents extending into 2032–2039, enhance the company’s international footprint and position its ANKTIVA-based regimens as a new chemotherapy-free backbone in immunotherapy for difficult-to-treat cancers in a region with significant unmet need.

The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

Spark’s Take on IBRX Stock

According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.

The score is held back primarily by weak financial health (losses, negative equity, and negative operating/free cash flow) despite strong revenue growth. Technically, the stock shows bullish trend strength but appears overbought, raising near-term pullback risk. Corporate events are a positive offset (notably the EMA nod for ANKTIVA®), while valuation remains constrained by ongoing losses and no dividend.

To see Spark’s full report on IBRX stock, click here.

More about ImmunityBio

ImmunityBio, Inc. is a vertically integrated, commercial-stage biotechnology company focused on developing next-generation immunotherapies and cell therapies to treat cancers and infectious diseases. Its platforms, including the FDA-designated Breakthrough Therapy ANKTIVA® for non-muscle invasive bladder cancer, are designed to bolster the natural immune system—activating NK cells, T cells and memory T cells—to provide durable responses while reducing reliance on traditional high-dose chemotherapy, with an emphasis on more effective, accessible and easily administered treatments than current standards of care.

Average Trading Volume: 11,545,592

Technical Sentiment Signal: Sell

Current Market Cap: $2.55B

Learn more about IBRX stock on TipRanks’ Stock Analysis page.